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General Discussion and Future Perspectives
In this thesis we investigated mechanisms to achieve long-term epigenetic reprogramming of endoge-
nous promoters by targeted Epigenetic Editing. We modulated the expression of several genes using 
artificial transcription factors (ATFs) and we also successfully induced epigenetic modifications in a 
gene-targeted manner to set the stage to permanently modulate expression. Epigenetic modifications 
are aberrantly altered in several diseases, including cancer. We have been successful in altering the 
epigenetic modifications on different loci, to show their involvement in disease progression or as thera-
peutic targets (Chapters 5-8). The potentials of Epigenetic Editing are yet to be fully discovered, but with 
the CRISPR/dCas revolution, we now can strive to understand the complexity of chromatin changes.
Although feasibility of Epigenetic Editing is shown in this thesis and by other studies, it requires 
further investigation to become a straightforward approach. The efficacy of the two main components of 
Epigenetic Editing (epigenetic effector domains and DNA binding domains) is very important to achieve 
the ultimate outcome: sustained gene expression reprogramming. The dominant functionality of the 
epigenetic marks that are written or erased in different microchromatin contexts determines the repro-
gramming capacity. There are various known and unknown factors influencing the function of epige-
netic modifications such as the genomic loci (target site: promoter, enhancer, CpG island Chapter 4), 
the crosstalk between epigenetic modifications (e.g. K4Me3 is not maintained in the presence of DNA 
methylation, Chapter 8), and the higher order chromatin context of cells (nucleosomal density, laminar 
associated domains). We used the Epigenetic Editing approach as a research tool to interrogate epige-
netic regulation mechanisms (Chapter 7, Chapter 8). Depending on the microchromatin environment, 
different effector domains might be effective. For example, the writing of H3K4me3 at gene promoters 
is able to induce gene re-expression, but the sustainability of such effect is only achieved when other 
factors are evaluated. Chromatin crosstalk plays an important role in this respect. In order to fully ex-
ploit this promising approach as a therapeutic option, the factors that influence the effect of epigenetic 
modifications need to be addressed first. In addition, to the epigenetic marks, the efficiency and spe-
cificity of DNA binding domains (ZFPs, TALEs and CRISPR-Cas) are factors to be taken into account 
for designing the Epigenetic Editing tools and ATFs. Here we briefly discuss some of these factors. 
Gene expression is regulated in several levels. At the transcriptional level, the regulation of 
gene expression is a result of complex interactions between the DNA sequence and the transcription 
machinery, as well as epigenetic modifications such as DNA methylation and histone modifications1,2. 
The position of epigenetic marks has been correlated with gene expression3. In order to exploit Epige-
netic Editing, it is necessary to write or erase modifications at the most suitable and relevant position 
of the target gene. In general, enhancers, and regions around the transcription start sites (TSSs) play 
essential roles in gene expression regulation. It has been shown that epigenetic modifications of the pro-
moter region are correlated with gene transcription. This correlation has been intensively investigated 
and in this regard the international ENCODE and the Epigenome Roadmap projects has provided the 
field of epigenetics and genetics with massive amount of data supporting this hypothesis4,5. Indeed, it 
has been demonstrated that epigenetic modifications can be used to predict gene expression. Ongoing 
debates are centered around the question whether the epigenetic marks are able to drive transcrip-
tional activation/repression or whether they are a mere consequence of the transcriptional activity6.
The most studied epigenetic marks are DNA methylation and histone post-translational mo-
difications. DNA methylation occurs mainly at CpG dinucleotides in the genome and is mediated by 
DNA methyltransferases (DNMTs). DNMTs are enzymes that catalyze the transfer of methyl groups 
from S-adenosyl-L-methionine to the 5’ position of cytosine, resulting in 5-methylcytosine (5mC)7. Se-
veral regions in our genome contain highly dense CpG dinucleotides and are called CpG islands8. 
Methylation of DNA in this CpG islands and other regions has been correlated with gene repression. 
For instance, DNA methylation of the promoter of imprinted genes is responsible for the allele-spe-
cific expression9. Additionally, It is commonly known that several silent (tumor suppressor) genes in 
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different types of cancer are aberrantly hypermethylated (Chapter 5, Chapter 8)10. Although it is not 
completely clear whether DNA methylation directly causes the gene silencing, induction of DNA me-
thylation on target genes by means of Epigenetic Editing was associated with their repression11-16. 
We have also showed in this thesis, that DNA methylation plays an important role in the memory of 
epigenetic repression (Chapter 8). This factor seems to be a key player in maintenance of gene re-
pression, since activation of the silenced EpCAM gene was only achieved after DNA demethylation 
of the promoter and the induction of H3K4me3. However, again, this is not a general rule, as other 
authors have conflicting results regarding the epigenetic memory of induced DNA methylation15,17. 
The N-terminal tails of the histone proteins can be modified (acetylation, methylation, ubiqui-
tination, phosphorylation and others) at different residues. The pattern of these modifications form 
a so-called histone code that can be deciphered by other proteins that can alter the structure of hi-
gher-order chromatin and recruit effector molecules18. Histone marks are reversible and can be as-
sociated with either euchromatin or heterochromatin and therefore can control gene expression. 
These histone modifications are classified as active or repressive marks; some of them like ace-
tylation of histones H3/H4 and methylation of histone H3 lysine 4 (H3K4me3), are classified as eu-
chromatin-related marks and are commonly associated with active transcription; whereas modi-
fications like methylation of lysine 9 or lysine 27 of histone H3 (H3K9me2/3 or H3K27me3), are 
considered as heterochromatin-related marks which are often related to gene repression1,18-21.
It is under debate whether histone modifications are causative in gene expression regulation. 
However, modulation of the target gene by induction of histone marks in the chromatin context was 
demonstrated first in 2002, by inducing H3K9 methylation and causing gene repression22. The last 
decade has seen the advancement of Epigenetic Editing as a tool to understand the causative role 
of epigenetic marks. It has been show that induction of DNA methylation at gene promoters was also 
able to induce repression, DNA demethylation could induce gene expression, histone modification such 
as demethylation of H3K9 at enhancers23 could induce expression as well as histone acetylation24. 
These studies have yielded an unprecedented and important amount of data to fire the debate be-
tween cause and consequence, and is now widely accepted that epigenetic marks can cause gene 
expression changes. Here we are able to reinforce this hypothesis by showing that induction of H3K9 
methylation can repress gene expression and that induction of H3K4me3 at promoters can induce 
expression. Furthermore we show that sustained gene reprogramming is a possibility depending on 
the epigenetic context. To understand how chromatin microenvironment can influence the sustaina-
bility, it is important to know how chromatin is regulated and how chromatin crosstalk takes place.
 Epigenetic crosstalk
Epigenetic modifications such as DNA methylation and histone marks interact and influence each 
other25,26. Such interactions or crosstalk include the co-localization of epigenetic modifications, recruit-
ment of binding-proteins by epigenetic marks, and the recruitment of epigenetic enzymes by other enzy-
mes seem to be necessary for maintaining the gene expression status27. DNA methylation and chroma-
tin modifications are thought to influence each other and, accordingly, molecular links between the two 
have been identified. Furthermore, the genome and the epigenome can also influence each other: CpG 
islands, for example are hotspots for histone modifications and there are non-coding RNA transcripts 
such as microRNAs, that regulate epigenetic modifiers8. Thus, both the genome and the epigenome 
and epigenetic modifications among themselves are thought to be closely interconnected. Deregula-
tions of these delicate balances are frequently observed in diseases such as cancer and are thought 
to drive tumorigenesis. Additionally, the pattern of de novo DNA methylation in early development may 
be dependent on the presence of histone modifications. For instance, (mono-, di-, or tri-) methylation 
of H3K4 is involved in the targeted repression of CpG island methylation in vitro and therefore plays a 
role in active transcription28,29. Furthermore, the methylation profile of progenitor cells is also believed 
to be important for maintenance of histone marks during cell division. Hypomethylated DNA regions are 
associated with a rather loosely packed open euchromatin that contains acetylated histones for mainte-
nance of transcription. In contrast, methylated DNA shows a hypoacetylated nucleosome configuration 
that is resembled by a tightly closed, repressive heterochromatin state. These facts support the notion 




There is convincing evidence that the presence of H3K4me3 prevents DNA methylation occurrence29. 
H3K4me3 is found on the nucleosomes which are flanking the nucleosome-free region of transcription 
start sites (TSSs) of actively transcribed genes, and it is of interest to know that de novo DNA methyla-
tion (using DNMT3L) require nucleosomes that contain unmethylated H3 lysine 4 to recruit the related 
DNMT enzymes28,30. So both presence of H3K4me3 as well as absence of nucleosomes around TSS 
can cause absence of DNA methylation. Here we were able to show that in the presence of DNA 
methylation, the induction of H3K4me3 is not enough for sustained re-expression of silenced genes. 
Moreover, the crosstalk between histone marks such as H2B ubiquitilation, H3K4me3 and H3K79me 
are synergistic in the regulation of gene transcription27,31,32. We have also demonstrated the importance 
of the presence of these two marks in order to successfully and sustainably induce gene expression.
DNA methylation and repressive histone marks at promoters and TSSs were found to co-localize 
as well. For instance, in inactive genes, DNA methylation of the promoter is accompanied with H3K9me3 
mark on nucleosomes at the TSS33-35. Alternatively, methylated DNA binding domain proteins were found 
to recruit histone deacetylases which, altogether, stabilize the repressive state of chromatin. Moreover, 
DNA methylation was found to direct H3K9me3 or H3K9me2 by recruiting epigenetic writers. Such cross-
talk can also occur through the direct interaction between epigenetic enzymes, such as co-recrutiment of 
DNMTs and H3K9 methylating enzymes. Indeed, such interactions are involved in spreading of epigenetic 
modifications along the genome. For example H3K9me3 is able to recruit HP1, heterochromatin binding 
protein, which interacts with SUV39H1 (H3K9 methylating enzyme), and is involved in spreading hete-
rochromatin marks36-38. HP1 can also interact with HDACs which further enhance the repressive state of 
chromatin. Here we show that induction of H3K9me is able to achieve sustained gene repression (Chap-
ter 7), which can be due to the recruitment of DNA methylation, but this requires additional experiments. 
Chromatin microenvironment
The expression of a single gene often varies in different cell types as well as in distinct levels of di-
fferentiation. The main reason is because although cells share identical genomes they have different 
epigenetic patterns39,40. Cells inherit their epigenetic patterns during cell divisions, thereby maintaining 
their gene-specific expression profiles. For instance, human embryonic and differentiated cells have 
distinguishable epigenomes. Embryonic cells have a high rate of bivalent promoters that have both 
active (H3K4me3) and inactive histone marks (H3K27me3)41, while differentiated cell types have their 
own distinct epigenetic patterns. DNA methylation patterns were found to be different among human in-
dividuals, and large scale studies showed that the inter-individual variation of DNA methylation patterns 
are more apparent in CpG poor regions than in CpG rich regions42,43. Additionally, assessing differentially 
methylated regions of imprinted genes in same tissue samples but between different individuals revea-
led a high degree of variability and patterns43.
We observed different efficiency of gene expression reprogramming when targeting two different 
genes that have different chromatin microenvironments. On one hand, while genes that lack DNA me-
thylation but are repressed by other epigenetic marks are easily to be efficiently re-expressed by addition 
of H3K4me3 (PLOD2 on C33a cells), genes that are hypermethylated lack show some level of upregula-
tion, but very minimal compared to VP64 (EpCAM on HeLa cells) (Chapter 8). Moreover the levels of gene 
upregulation or downregulation observed in the same gene but different cell lines also differ, as seen for 
RASSF1A, ICAM1, EpCAM and TCTN2 (Chapters 6 and 8). Also the differences seen in the context de-
pendent repression or upregulation of the two transcripts of RASSF1 in two cell lines where one has active 
transcript A and C (HeLa), and the other has silenced A and active C (MCF7) (Chapter 5). When targeting 
the RASSF1c promoter with several effector domains we observed upregulation in HeLa, independent of 
the effector domain. This difference might be due to different epigenome contexts. Our observations and 
studies investigating epigenetic context variations suggest that the function of epigenetic modifications 
is dependent on the microchromatin context they are located in. Understanding epigenetic features/sig-
natures of different cell types in normal situation is required and helpful for unraveling epigenetic modi-
fications underling diseases including cancer and for restoring the normal epigenetic feature/signature.
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DNA binding proteins, advanta-
ges and disadvantages
The DNA binding domain plays a critical role in the specificity of the Epigenetic Editing approach. In 
this thesis we have used both Zinc Finger Proteins (ZFPs) and the CRISPR-Cas9 system to achieve 
gene expression modulation. Both systems have their advantages and disadvantages, as we have 
discussed in Chapter 2 and 4 of this thesis. These chapters dealt with the main impairments to tar-
get these specific domains in the context of chromatin. We reviewed the recent developments in the 
Epigenetic Editing field and listed the most important factors currently known to affect their efficiency 
at transcriptional modulation. Despite extensive characterization, the nature of their variability is sti-
ll a pressing problem for their development into therapies and use in large scale unbiased screens. 
The most studied platform has been the ZFPs, which where the first to be developed and stan-
dardized. Various studies have shown that the specificity of ZFPs is less than expected. Mapping the 
binding sites of different ZFPs and comparing them has revealed insightful data and provides useful in-
formation for designing more specific ZFPs44-47. On the positive side, ZFPs are less immunogenic and 
smaller, which has advantages for delivering. Additionally, we have showed that, in contrast to CRIS-
PR-Cas9, ZFPs have fewer limitations when targeting dense chromatin or hypermethylated regions.
Cas9 has fundamentally different binding characteristics to other platforms that may make it 
uniquely susceptible to certain epigenetic modifications of DNA. Recent insights indicate that nucleoso-
mes are strong suppressors of binding, but fail to transfer effectively to in vivo prediction48-51. The role of 
methylation has been the best investigated in Cas9 nuclease application and does not seem to affect 
cleavage efficiency52,53. Effective transcriptional modulation of hypermethylated genes has also been 
reported54-59. Furthermore, CpG islands do not prevent functional binding of Cas9 nuclease and Cas9 
transcription factors, but may reduce binding of Cas9 when combined with hypermethylation (Chapter 4).
Transcriptional activation likely requires persistent binding by dCas9 to continually act on the 
nearby promotor, in contrast, for nuclease applications where Cas9 only needs to access the DNA 
once to succeed in cleaving its target. It could be that the role of nucleosomes are underestimated be-
cause Cas9 can take advantage of relatively brief nucleosome turnover during replication. In contrast, 
dCas-based ATFs would need to have persistent presence and could therefore be more susceptible to 
nucleosomes and other DNA binding proteins. If the effects of CpG Island hypermethylation are media-
ted in a similar method this could explain why, in the limited amount of research published on this topic 
to date, no convincing functional ATF binding is generally found for sgRNAs targeting hypermethylated 
CpG islands although effective cleavage is frequently reported for such regions.  It is clear that many 
factors influence ATFs and nuclease uses of Cas9, and has different results even when targeting the 
same locus in different cell lines. Without direct investigation of this topic it is not possible to conclude 
from the current literature if CpG islands are an important factor in determining Cas9 ATF efficiency.
Conclusion and Future 
Perspectives
Epigenetic Editing is a powerful research tool to modulate the expression of genes and to increase 
our understanding of the role of epigenetic modifications in gene regulation. Nevetherless, there are 
important factors which should be addressed and evaluated in order to develop this robust technique to 
be used as a therapeutic option. Factors such as microchromatin environment and epigenetic crosstalk 
have to be further investigated since they influence functions of epigenetic modifications. Although, the 
never ending debate whether epigenetic modifications are a cause or consequence of transcription is 
still unclear, in this thesis we could show that epigenetic modifications are causative of gene expression/
repression. Understanding how the epigenetic modifications interact with each other and the microchro-
matin environment is key in order to achieve a sustained effect in gene expression modulation, allowing 
epigenetic inheritance and memory.
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Our studies and other Epigenetic Editing studies have demonstrated the efficacy of the technique in 
modifying the local epigenetic marks. In this thesis we took the technique a step forward, trying to un-
derstand how sustainability and heritability of these marks can be achieved. The inducible expression 
system was successful for studying gene expression regulation [Chapter 8]. We were able to further 
identify crosstalk between epigenetic modifications that made it possible to achieve long-term re-ex-
pression. Moreover, we distinguished how microchromatin environment can affect the outcome of gene 
induction/repression.  There is still a lot of unanswered questions that requires further study. It is getting 
more apparent that epigenetic marks interact, and their interactions are essential for their sustained 
effect on gene expression modulation11. It seems that efficiency of the Epigenetic Editing approach on 
gene expression can be improved via co-targeting multiple key epigenetic modifications (Chapter 8). Im-
proving the targeting platforms is also important to achieve efficient and specific targeting. It is important 
to understand where to target each DNA binding domain, depending on local properties of the regulatory 
regions in the genome (Chapter 4). When the technique is standardized, the promise of the curable ge-
nome will be a step closer. Due to the genome-wide side effects of current epigenetic drugs, Epigenetic 
Editing, in future, will be a good candidate as an alternative or in combination with other treatments for 
cancer and other epigenetic-related diseases.
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